ADRs quickly rose 14% on a report that Halozyme Therapeutics (HALO) has expressed takeover interest. Halozyme has recently ...

Van ECK Associates Corp reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 35.5% in the 3rd quarter, according to the company in its most recent 13F filing with the ...

A $1000 investment made in November 2014 would be worth $6,540.57, or a gain of 554.06%, as of November 8, 2024, according to our calculations. This return excludes dividends but includes price ...

Verdence Capital Advisors LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.9% in the third quarter, according to the company in its most recent 13F ...

What if you'd invested in Halozyme Therapeutics (HALO) ten years ago? It may not have been easy to hold on to HALO for all that time, but if you did, how much would your investment be worth today?

TD Cowen analyst Brendan Smith maintained a Buy rating on Passage Bio (PASG – Research Report) today. The company’s shares opened ...

In a report released today, Brendan Smith from TD Cowen reiterated a Buy rating on 908 Devices (MASS – Research Report). The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...